The pharmaceutical company is studying a third dose of the vaccine and a pneumococcal vaccine candidate.
[Ads /]
The trial is looking at safety when the vaccines are co-administered, and will follow up six months later.
Pneumococcal vaccines help prevent illnesses like pneumonia.
Six hundred adults over the age of 65 are in the trial.
[Ads /]
Some will receive both shots, others just one shot and a placebo.